Research update


Orexo: Zubsolv Rx data in June and raised forecast ahead of 2Q18 report

The market share for Zubsolv had favourable development in June, and it increased to 5.3% (Rx) and 5.7% (quantity), according to latest data from Symphony Health Solutions (July the 6th). Ahead of the 2Q18 report, we raise our expectations slightly. The result is scheduled to be announced before the market opens on the 11th of July.

Continue reading (pdf) icon-download